广州达安基因股份有限公司

Group 1 - The company reported total assets of 11,191.56 million yuan and net assets of 2,228.54 million yuan as of June 30, 2025, with an operating income of 0.00 million yuan and a net loss of 45.18 million yuan [2] - The company has a stake of 33.24% in Guangzhou Changtong Medical Technology Co., Ltd., which constitutes an associated relationship [2] - Shanghai Dashan Biotechnology Co., Ltd. is a subsidiary in which the company holds a 21.788% stake, establishing an associated relationship [3] Group 2 - YunKang Health Industry Investment Co., Ltd. is another subsidiary where the company holds a 46.9566% stake, indicating an associated relationship [6] - Guangzhou Sai Jun Biotechnology Co., Ltd. is a joint venture with a 32.63% stake held by the company, also indicating an associated relationship [8] - Guangzhou Financial Holdings Group Co., Ltd. holds a total of 31.63% of the company's shares through its subsidiaries, establishing an associated relationship [10] Group 3 - The company expects to have daily related transactions with Guangzhou Tiancheng Medical Technology Co., Ltd. not exceeding 0.50 million yuan in 2025 [11] - Expected daily related transactions with Guangzhou Changtong Medical Technology Co., Ltd. and its subsidiaries are projected to be no more than 0.01 million yuan [12] - The company anticipates daily related transactions with Shanghai Dashan Biotechnology Co., Ltd. to be up to 5.00 million yuan [13] Group 4 - The company follows a pricing policy based on market fair prices for its related transactions, ensuring transparency and fairness [16] - All related transactions are formalized through written agreements detailing transaction terms, pricing principles, and payment methods [17] - The purpose of these transactions is to support the company's operations and development, leveraging the advantages of associated parties to enhance sales and reduce costs [18] Group 5 - The independent directors of the company have reviewed and approved the related transaction proposals, affirming their alignment with the company's strategic development and benefit to overall efficiency [19] - The board's decision-making process regarding these transactions adhered to legal and regulatory requirements, ensuring no harm to the interests of shareholders [19]